Fungal Nail Infection News and Research

RSS

Fungal infections can affect skin, hair as well as nails. Nail infections are common especially in susceptible individuals. It leads to discoloured, ugly and misshapen nails that may even become painful.

New antifungal drugs could be developed based on substance bacteria use to decompose mushrooms

Soft rot diseases cause a great deal of damage in agriculture, and turn fruits, vegetables, and mushrooms to mush. By using imaging mass spectrometry together with genetic and bioinformatic techniques (genome mining), German researchers have now discovered the substance the bacteria use to decompose mushrooms.

29 Nov 2012

Sprucing up treatment for fungal nail infection

A lacquer containing resin from the Norway spruce shows promise as a treatment for onychomycosis, suggest results from an exploratory study.

9 Nov 2012

Primcogent Solutions introduces low level laser therapy for onychomycosis

Primcogent Solutions - supplier of the revolutionary ZERONA non-invasive body contouring technology in North America and Western Europe - has announced the launch of Lunula Laser, a clinically proven, low level laser therapy for onychomycosis, for distribution exclusively in Europe.

19 Jul 2012

Meda acquires exclusive licensing rights to Nalox from Moberg Derma

Meda has acquired exclusive licensing rights to Nalox (treatment of fungal nail infections/nail psoriasis) from Moberg Derma AB.

19 Sep 2011

PinPointe FootLaser receives FDA clearance for treatment of nail fungus

The podiatry practice of Mark E. Spier, DPM, announced today that the PinPointe™ FootLaser™ has received clearance from the U.S. Food and Drug Administration (FDA) for the treatment of nail fungus (onychomycosis). Dr. Spier is the first certified provider of the treatment in the Baltimore area.

26 Oct 2010

Isogenica, NovaBiotics to accelerate the development of peptide anti-infective technology

Isogenica Ltd, today announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of NovaBiotic's platform peptide anti-infective technology.

6 Oct 2010

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).

30 Apr 2010